Stockscreener 앱 받기
13.25
0.76%
0.10
전일 마감가:
$13.15
열려 있는:
$12.94
하루 거래량:
1.31M
Relative Volume:
0.70
시가총액:
$1.18B
수익:
$71.64M
순이익/손실:
$-294.57M
주가수익비율:
-3.9576
EPS:
-3.348
순현금흐름:
$-84.46M
1주 성능:
+4.66%
1개월 성능:
+39.92%
6개월 성능:
+54.97%
1년 성능:
+62.98%
1일 변동 폭
$12.89
$13.27
1주일 범위
$12.43
$13.41
52주 변동 폭
$7.3575
$13.90
Kura Oncology Inc Stock (KURA) Company Profile
명칭
Kura Oncology Inc
전화
(858) 500-8800
주소
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
13.25 | 1.04B | 71.64M | -294.57M | -84.46M | -3.348 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 개시 | Lake Street | Buy |
| 2025-09-04 | 개시 | Guggenheim | Neutral |
| 2025-02-06 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-08-11 | 개시 | BofA Securities | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-05-17 | 개시 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2022-07-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-02-15 | 개시 | Jefferies | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-07 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-11-05 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | 개시 | Credit Suisse | Outperform |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2018-11-09 | 개시 | Piper Jaffray | Overweight |
| 2018-08-01 | 개시 | H.C. Wainwright | Buy |
| 2016-10-13 | 재개 | Leerink Partners | Outperform |
| 2016-01-22 | 개시 | JMP Securities | Mkt Outperform |
| 2015-12-30 | 개시 | Oppenheimer | Outperform |
| 2015-12-16 | 개시 | Citigroup | Buy |
모두보기
Kura Oncology Inc 주식(KURA)의 최신 뉴스
Kura Oncology (KURA) Chief Legal Officer Teresa Bair Sells 31,48 - GuruFocus
Kura Oncology (NASDAQ:KURA) Insider Sells 31,487 Shares - MarketBeat
Kura Oncology (NASDAQ: KURA) affiliate flags 4,345-share Rule 144 sale - Stock Titan
Kura Oncology (KURA) counsel offloads shares via 10b5-1 plan - Stock Titan
Great Lakes Advisors LLC Invests $2.85 Million in Kura Oncology, Inc. $KURA - MarketBeat
Kura Oncology (KURA) Q2 2026 Earnings Call Transcript - The Globe and Mail
Kura Oncology (NASDAQ: KURA) exec plans to sell 31,487 shares - Stock Titan
Kura Oncology (KURA) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Kura Oncology (NASDAQ:KURA) Gains Traction With Its AML Menin Inhibitor - Kalkine Media
Troy Wilson Bought 12% More Shares In Kura Oncology - simplywall.st
Teleconferência de Resultados do 2º Trimestre de 2026 da Kura Oncology (KURA): Vendas do KOMZIFTI Atingem US$ 9,1 Milhões - TradingKey
Kura Oncology (NASDAQ:KURA) Hits New 52-Week High Following Insider Buying Activity - MarketBeat
Kura Oncology stock hits 52-week high at 12.49 USD - Investing.com
Does Kura Oncology (KURA) Have the Potential to Rally 178.55% as Wall Street Analysts Expect? - Yahoo Finance
Why Kura Oncology (KURA) Is Up 14.5% After New Ziftomenib Resistance Data And Q2 Results - Yahoo Finance
Kura Oncology stock rises on CEO insider purchase By Investing.com - Investing.com South Africa
Why Is KURA Stock Rallying 8% After-Hours? - TradingView
Kura Oncology stock rises on CEO insider purchase - Investing.com
Kura Oncology CEO Troy Wilson Acquires 100,000 Shares at $11.12 Each - Kalkine Media
Troy Edward Wilson Purchases 100,000 Shares of Kura Oncology (NASDAQ:KURA) Stock - MarketBeat
Kura Oncology (NASDAQ: KURA) CEO buys more in 100,000-share insider trade - Stock Titan
Kura Oncology Inc (KURA) (Q2 2026) Earnings Call Highlights: KOM - GuruFocus
Kura Oncology Q3 EPS Increased by Brookline Capital Markets - MarketBeat
Q3 EPS Estimates for Kura Oncology Boosted by HC Wainwright - MarketBeat
Kura Oncology (KURA) investors report up to 9.7% beneficial ownership stakes - Stock Titan
Kura Oncology (NASDAQ:KURA) Stock Price Up 8% on Analyst Upgrade - MarketBeat
A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $23 to $40 - Moomoo
Kura Oncology Q2 2026 Earnings Call Highlights Precision Oncology StrategyPretax Income Report - vinanet.vn
Kura Oncology FY2029 EPS Cut by Brookline Capital Markets - MarketBeat
Kura Oncology (KURA) Receives a Buy from Bank of America Securities - The Globe and Mail
Kura Oncology (KURA) Q2 2026 Earnings Call: KOMZIFTI-Umsatz erreicht 9,1 Mio. USD - TradingKey
Lake Street Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $23 - Moomoo
BofA Securities Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $31 - Moomoo
Kura Oncology, Inc. Stock 12‑Month Price Target Raised to $32, Implies 222% Upside - TradingView
Kura Oncology (NASDAQ:KURA) Shares Gap Up After Strong Earnings - MarketBeat
KURA Maintained by Wedbush -- Price Target Raised to $38 - GuruFocus
Kura Oncology (NASDAQ:KURA) Price Target Raised to $38.00 at Wedbush - MarketBeat
Wedbush Adjusts Price Target on Kura Oncology to $38 From $36, Keeps Outperform Rating - marketscreener.com
Kura Oncology (NASDAQ:KURA): What Does the Latest Update Mean for Clinical Evidence? - Kalkine Media
Kura Oncology, Inc. Stock 12‑Month Price Target Raised to $31.83, Implies 220% Upside - tradingview.com
Kura Oncology (KURA) Q2 2026 Results Highlight Valuation Challen - GuruFocus
Kura Oncology Q2 2026 Earnings Call Transcript - MarketBeat
Kura Oncology, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Kura Oncology Q2 EPS $(0.77) beats estimate, sales miss - scanx.trade
Kura Oncology Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: Kura Oncology tops Q2 2026 estimates as launch gains - Investing.com
Kura Oncology (NASDAQ:KURA) Issues Earnings Results - MarketBeat
Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Kura Oncology, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Kura Oncology Inc (KURA) Reports Q2 Revenue of $20.9M with Net L - GuruFocus
Kura Oncology Q2 Diluted Loss Widens, Revenue Rises - marketscreener.com
Kura Oncology Inc (KURA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Kura Oncology Inc 주식 (KURA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Powl Brian T. | Chief Commercial Officer |
Aug 21 '26 |
Sale |
11.89 |
4,345 |
51,663 |
169,269 |
0.86%
0.31%
자본화:
|
볼륨(24시간):